Merdury Biopharmaceutical

Merdury Biopharmaceutical EBIT per Share

The EBIT per Share of Merdury Biopharmaceutical (6932.TWO) as of Oct 18, 2026 is -0.15 TWD. In the previous year, EBIT per Share was -0.12 TWD — a change of 26.84% (lower).

EBIT per Share

-0.15TWD

YoY

26.84%

Last updated:

EBIT per Share of Merdury Biopharmaceutical is 2025 -0.15 TWD. EBIT per Share of Merdury Biopharmaceutical was 2024 -0.12 TWD. It decreases by 26.84% lower compared to the previous year.

The Merdury Biopharmaceutical EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2019
-0.00 TWD
Jan 1, 2020
-0.00 TWD
Jan 1, 2021
-0.01 TWD
Jan 1, 2022
-0.08 TWD
Jan 1, 2023
-0.10 TWD
Jan 1, 2024
-0.12 TWD
Jan 1, 2025
-0.15 TWD
The Merdury Biopharmaceutical EBIT per Share history
YEAREBIT per ShareYoY
-0.15TWD+26.84%
-0.12TWD+14.00%
-0.10TWD+34.84%
-0.08TWD+563.59%
-0.01TWD+2,422.86%
-0.00TWD-6.25%
-0.00TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Merdury Biopharmaceutical Stock analysis

What does Merdury Biopharmaceutical do? Merdury Biopharmaceutical Corp is a pharmaceutical company based in Taipei, Taiwan, operating within the Health Care sector. The company has a small workforce of 13 employees and went public on December 23, 2022, with its ticker listed as 6932.TWO. Merdury Biopharmaceutical Corp focuses on developing drugs that address unmet medical needs, difficult generic drugs, and second-class new drugs. The company utilizes a self-developed drug development platform called StackDose, which enables the creation of tablets with controlled dissolution properties, allowing for either immediate or sustained drug release. This technology supports the development of products such as Sildenafil, Metformin, Tadalafil, Zolpidem, angina treatments, migraine medications, and multi-ingredient antihypertensive drugs. These products are primarily marketed and sold in Taiwan and the United States. The company's website is https://merdury.com, providing further information about its operations and offerings. Merdury Biopharmaceutical Corp operates as a publicly traded entity with a focus on innovative pharmaceutical solutions within the Taiwanese and U.S. markets. Merdury Biopharmaceutical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Merdury Biopharmaceutical stock

EBIT per Share of Merdury Biopharmaceutical is -0.15 TWD in 2025.

EBIT per Share of Merdury Biopharmaceutical changed from -0.12 TWD to -0.15 TWD, representing a 26.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Merdury Biopharmaceutical since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Merdury Biopharmaceutical

All Key Metrics — Merdury Biopharmaceutical